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apy mobilization and growth factor administration. Apheresis per-
formed on the week-end may increase resource utilization com-
pared to apheresis during the week. In order to decrease the
likelihood of week-end collections, we analyzed the timing of
apheresis with respect to chemotherapy administration and devel-
oped an optimized schedule for chemotherapy, growth factors, and
apheresis. Methods: A retrospective analysis of mobilization of
auto-grafts in 41 patients with lymphoid malignancies (NHL, MM,
HD) was performed. Chemotherapy mobilization regimes in-
cluded cyclophosphamide (n  14), CHOP, ICE, or VTEPA (n 
15), Hyper CVAD (n  8), or DT-PACE (n  4). G-CSF was
administered S.Q. once daily at a dose of 5 mcg/kg starting two
days after the last day of chemotherapy. GM-CSF was added at a
dose of 5 mcg/kg every evening starting on the 8th day after
chemotherapy. Apheresis began when the blood CD34 cells
were  20/uL. Results: The median number of CD34 cells
collected in all 66 patients was 8  10E6/kg (range 1 to 79 
10E6/kg) following a median of 2 days of apheresis. The median
number of days between the last day of chemotherapy and the ﬁrst
day of apheresis was not signiﬁcantly different between the entire
cohort of 66 patients (median 12 days, range 8-24 days) or the
subsets of patients who received cyclophosphamide (12 days),
CHOP, ICE, or VTEPA (11 days), Hyper CVAD (11 days) or
DTPACE (15 days). Among the initial 41 patients analyzed, 29%
of patients required apheresis during the week-end. Administration
of the last dose of chemotherapy on Thursday/Friday versus Tues-
day/Wednesday was associated with a reduced rate of week-end
apheresis collections (p  0.009). An optimized schedule of che-
motherapy ending on Friday was implemented in order to avoid
week-end collections and applied in 25 subsequent patients. Using
the new schema for chemo-mobilization the incidence of week-end
apheresis was reduced to 14% in the next group of 14 patients.
Among 11 patients not treated according to the new schema, the
incidence of week-end collections was 27%. Conclusion: The ﬁrst
day of apheresis can be generally predicted as occurring 11-15 days
after the last dose of chemotherapy using a combination of G-CSF
and GM-CSF treatment when these growth factors are sequentially
administered 2 and 8 days after the last dose of chemotherapy.
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IMPACT OF AGE ON OUTCOME OF AUTOLOGOUS STEM CELL TRANS-
PLANT FOR FOLLICULAR AND DIFFUSE LARGE B CELL LYMPHOMA
Arora, A., Vose, J.M., Lynch, J., Armitage, J.O., Bierman, P., Bociek,
G.R., Weisenburger, D.D. University of Nebraska Medical Center,
Omaha, NE
Incidence of Non-Hodgkins Lymphoma (NHL) rises with age.
The median age of diagnosis is 60 years. We report the impact of
age on the outcome of patients who received high dose chemo-
therapy and autologous hematopoietic stem cell transplant (HDC/
AHSCT) for follicular or diffuse large B cell lymphoma from April
1983 to June 2001. 50/484 (10%) were age 60 years with median
age of 65 years (range: 60-73). 434/484 (90%) were 60 years of
age with median age of 45 years (range 16-59). Patients 60 years
and above were more likely to have diffuse large B cell lymphoma
(84% Vs 51%, p 0.0001). Stage 3 or 4 disease was more common
in patients 60 years (32% Vs 48%, p  0.03). Other character-
istics which includes: median time from diagnosis to transplant,
number of prior chemotherapies, extranodal involvement, disease
status at transplant, LDH level and chemosensitivity did not show
any signiﬁcant differences between the two age groups. Approxi-
mately 30% of patients in each age group had received three or
more chemotherapies. Majority of the patients received BEAC/
BEAM as the conditioning regimen with peripheral hematopoietic
stem cells as the source of transplant. The median follow-up of
surviving patients was 5.9 years (range 1.5-19.2). Patients 60 years
and above had a signiﬁcantly poor 5-year event free survival rate
(27% Vs. 39%, p  0.01) and overall survival rate (31% Vs. 54%,
p  0.01) when compared to patients less than 60 years of age. On
multivariate analysis, age60 years (HR 4.4, 95% CI 1.7-11.6, p
0.01) and use of three or more chemotherapy regimens (HR 2.2,
95% CI 1.2-4.1, p  0.01) were independent risk factors for an
adverse event. Age 60 years (HR 6.5, CI 2.1-20.2, p  0.01),
female sex (HR 2.1, 95% CI 1.1-4.1, p  0.03), use of three or
more chemotherapy regimens (HR 2.9 95% CI 1.4-5.7, p  0.01),
disease resistant to chemotherapy (HR 3.5, 95% CI 1.3-9.6, p 
0.01) were independent risk factors for death. In conclusion, ad-
vanced age is a strong and independent risk factor for outcome.
AHSCT should be offered early in the course of relapse. Various
strategies that include immunotherpy and other novel treatment
are needed to improve chemoresistance in patients receiving
HDC/AHSCT.
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HIGH DOSE SEQUENTIAL (HDS) FOLLOWED BY AUTOLOGOUS BONE
MARROW TRANSPLANTATION (ABMT) AS SALVAGE TREATMENT IN
ADVANCED HODGKIN’S DISEASE (HD)
Delamain, M.T., Cardoso, R.B., Pagnano, K.B., Oliveira, G.B., Lo-
rand-Metze, I., Vigorito, A.C., Aranha, F.J.P., Eid, K.B., Miranda,
E.C.M., De Souza, C.A. Hematology and Blood Transfusion Center-
State University of Campinas-UNICAMP, Campinas, Sa˜o Paulo, Brazil
ABMT has been proposed as a salvage treatment of resistant/
refractory HD. HDS using Cy 7g/m2 for debulking and PBPC
mobilization followed by MTX 8g/m2 and then VP-16 2g/m2
before ABMT, described by Milan group, seems to be effective in
these patients. We report the results obtained using this procedure
in 31 patients with HD who failed conventional therapy or relapsed
within 24 months of conventional chemo /radiotherapy. Pa-
tients were treated with HDS followed by ABMT receiving BEAM
(BCNU, Etoposide, Ara-C and Melphalan) as conditioning regi-
men. The median age was 25 years (12-61), 20 male (64,5%) and
11 female (35,5%). The histology at diagnosis showed: 19 (61,3%)
nodular sclerosis; 9 (29%) mixed cellularity; 2 (6,5%) lymphocyte-
depleted and 1 (3,2%) lymphocyte-rich HD. Bulky disease was
presented in 15/31 (49%) patients and 6/31 (20%) had bone mar-
row inﬁltration. The Overall survival (OS) and disease free survival
(DFS) were 49% (n  31) and 60% (n  15), respectively, in 1825
days. The OS was 62% for patients with 0-1 prognostic factors at
diagnosis and a shorter OS was observed in patients with more than
2 prognostic factors (P  0.004). Bulky disease , histology type and
bone marrow involvement did not correlate with poor outcome.
Fifteen patients died, 8/15 due to progressive disease (53%), 5/15
due to toxicity after the HDS (33%) and 2/15 due to toxicity after
ABMT (13%). Status presens for alive patients after a median time
of 783 days (range 50-1929) from transplant is: CR 11 (35,5%),
partial response 2 (6,5%) and 4 in progressive disease (12,9%). We
conclude that HDS followed by ABMT is an effective salvage
regimen for patients with resistant/refractory Hodgkin’s disease
and probably induces a long and stable CR mainly in chemosen-
sitive patients. Patients presenting 2 prognostic factors at diag-
nosis presented worst outcome.
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AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA
AND LYMPHOMA WITHOUT TRANSFUSION SUPPORT
Ford, P.A.1, Matthews, B.A.2 1. Pennsylvania Hospital, Philadelphia,
PA; 2. Pennsylvania Oncology Hematology Associates, Philadelphia, PA
High-dose chemotherapy (HDCT) and autologous peripheral
blood stem cell transplantation (APBSCT) results in signiﬁcant
anemia and thrombocytopenia with transfusion support felt to be
necessary in all patients. Our center was the ﬁrst to perform stem
cell transplantation without the use of blood products in Jehovah
Witness’s who decline transfusions based on religious convictions.
Table. Relationship Between Timing of Chemotherapy and Percentage
of Patients Pheresed on Weekends
Last Day of
Chemo Sunday Monday Tuesday Wednesday Thursday Friday Saturday
% pheresed
Saturday
or Sunday 11% 33% 44% 50% 0% 16% 25%
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